Li Xie - Sinphar Pharmaceutical Accounting Head

All Insiders . Taiwan . 
Stock . Sinphar Pharmaceutical Co . Stakeholders . Insider . Li Xie
1734 Stock  TWD 31.25  0.10  0.32%   

Insider

Li Xie is Accounting Head of Sinphar Pharmaceutical Co
Phone886 0 3958 1101
Webhttps://www.sinphar.com.tw

Sinphar Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0207 % which means that it generated a profit of $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0444 %, meaning that it generated $0.0444 on every $100 dollars invested by stockholders. Sinphar Pharmaceutical's management efficiency ratios could be used to measure how well Sinphar Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Sinphar Pharmaceutical Co has accumulated 1.49 B in total debt with debt to equity ratio (D/E) of 51.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sinphar Pharmaceutical has a current ratio of 2.21, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sinphar Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sinphar Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sinphar Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sinphar to invest in growth at high rates of return. When we think about Sinphar Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

YuI LeeYungShin Global Holding
N/A
Chih HuangPhytohealth Corp
N/A
Zhi PanYungShin Global Holding
N/A
BaoKun LaiEverlight Chemical Industrial
N/A
KuoPin WengEverlight Chemical Industrial
N/A
Ying XuWellell
N/A
Yi LiPhytohealth Corp
N/A
Ming ZhangWellell
N/A
BaiLi SungEverlight Chemical Industrial
N/A
Wen ShiWellell
N/A
YaoXing HuangEverlight Chemical Industrial
N/A
Xiu LinWellell
N/A
Daniel LeeWellell
N/A
Bo XueWellell
N/A
ChihWei ChienYungShin Global Holding
N/A
YiLi LeePhytohealth Corp
N/A
ChongKun HsiaoEverlight Chemical Industrial
N/A
Kevin LinPhytohealth Corp
N/A
Zhi HuangWellell
N/A
Alan ChangWellell
N/A
SiFeng ChenEverlight Chemical Industrial
N/A
,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. ,Ltd. was founded in 1977 and is headquartered in Yilan, Taiwan. SINPHAR PHARMACEUTICAL operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange. Sinphar Pharmaceutical Co (1734) is traded on Taiwan Stock Exchange in Taiwan and employs 26 people.

Management Performance

Return On Equity0.0444
Return On Asset0.0207

Sinphar Pharmaceutical Management Team

Elected by the shareholders, the Sinphar Pharmaceutical's board of directors comprises two types of representatives: Sinphar Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinphar. The board's role is to monitor Sinphar Pharmaceutical's management team and ensure that shareholders' interests are well served. Sinphar Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinphar Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
ChihHsiao Chen, Head of Finance
Zhiwen Li, Chairman of the Board
Li Xie, Accounting Head

Sinphar Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sinphar Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0444
Return On Asset0.0207
Profit Margin0.07 %
Operating Margin0.07 %
Current Valuation6.26 B
Shares Outstanding167.72 M
Shares Owned By Insiders20.27 %
Shares Owned By Institutions1.49 %
Price To Earning536.84 X
Price To Book1.88 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Additional Tools for Sinphar Stock Analysis

When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY